Madrigal Pharmaceuticals, Inc. (MDGL)
- Previous Close
208.04 - Open
208.33 - Bid 206.90 x 100
- Ask 207.41 x 100
- Day's Range
200.08 - 209.89 - 52 Week Range
119.76 - 302.68 - Volume
359,471 - Avg. Volume
553,309 - Market Cap (intraday)
4.41B - Beta (5Y Monthly) -0.34
- PE Ratio (TTM)
-- - EPS (TTM)
-19.99 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
368.79
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
www.madrigalpharma.comRecent News: MDGL
Performance Overview: MDGL
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MDGL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MDGL
Valuation Measures
Market Cap
4.43B
Enterprise Value
3.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
10.94
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-10.87
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.13%
Return on Equity (ttm)
-88.78%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-444.28M
Diluted EPS (ttm)
-19.99
Balance Sheet and Cash Flow
Total Cash (mrq)
1.06B
Total Debt/Equity (mrq)
13.84%
Levered Free Cash Flow (ttm)
-229.94M
Research Analysis: MDGL
Company Insights: MDGL
MDGL does not have Company Insights